The Testosterone Warning That Isn't About the Man Taking It

Testosterone gel carries a boxed warning — the strongest warning the FDA applies — and it is not about a risk to the man using it. It concerns secondary exposure: testosterone transferring from a treated man's skin to someone else's. Virilization has been reported in children exposed this way, and while signs generally regressed once exposure stopped, in a few reported cases enlarged genitalia did not fully return to age-appropriate size and bone age remained modestly advanced.[1]

That is an unusual shape for a drug warning, and it is worth understanding on its own terms.

What the warning actually says

The reported signs and symptoms in secondarily exposed children include enlargement of the penis or clitoris, development of pubic hair, increased erections and libido, aggressive behaviour, and advanced bone age.[1]

Two details matter for anyone weighing this.

Most cases regressed. Once the exposure was removed, signs and symptoms generally resolved.[1]

Not all of them fully did. In a few cases enlarged genitalia did not completely return to age-appropriate normal size, and bone age remained modestly greater than chronological age.[1] Advanced bone age is the consequential one — it is not a cosmetic finding.

The label also records that the risk of transfer was increased in some of these cases by not adhering to the precautions for appropriate use.[1] Which means the warning describes a preventable mechanism, not an unavoidable one.

The precautions the label specifies

Directly from the labelling:[1]

• Children and women should avoid contact with unwashed or unclothed application sites on a man using the gel.
• Patients should wash hands with soap and water immediately after applying.
• The application site should be covered with clothing once the gel has dried.

Why this is a formulation question

Any testosterone applied to skin creates a treated surface, and that surface is the transfer route. The variables that determine the risk are how much drug sits on the skin, over how large an area, for how long before it is absorbed and dry, and whether the site can be covered.

That makes it a reasonable question to ask about any topical testosterone, including a spray. The published pharmacokinetic work on the transdermal spray platform Keen uses is set out in the published clinical evidence — and the transfer precautions still apply. Washing hands, letting the application dry before skin-to-skin contact, and keeping the site covered are requirements of topical testosterone as a class, not of one product.

Nothing about a formulation removes the need to ask who else lives in the house.

What to do about it practically

Tell your prescriber who you live with. Young children in the home, or a partner who is pregnant or may become pregnant, are relevant clinical information.

Follow the timing, not just the steps. The label's precaution is to cover the site once the gel has dried[1] — drying time is part of the instruction, and rushing it is the common failure.

Treat a change in a child as urgent. Early pubic hair, genital enlargement or unusual aggression in a child in a household with topical testosterone warrants prompt medical attention, and the exposure is worth mentioning explicitly.

Frequently asked questions

Can it transfer to my partner? The label's precautions name both children and women in relation to contact with unwashed or unclothed application sites.[1] The precautions exist for the household, not only for children.

Is a shower enough before contact? The labelled precautions are handwashing immediately after application and covering the site once dry.[1] Follow the specific instructions for the product you are prescribed rather than substituting a general routine.

Does this apply to injections? No. Transfer is a property of a treated skin surface, so it is specific to topical formulations. Injections carry a different risk profile entirely.

Should this rule out topical testosterone if I have young children? It is a factor to weigh with your clinician, not an automatic disqualification — the label frames the risk as increased when precautions are not followed.[1] The point is that it belongs in the decision.

The question that belongs in the consultation

"Who else will be in contact with the application site, and what does that mean for the formulation you're recommending?" It is a question about the people around you, and it is the reason this warning exists at all.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: Keen vs Hims and the published clinical evidence.

References

1 source

1. U.S. Food and Drug Administration. AndroGel (testosterone gel) 1% — prescribing information, including BOXED WARNING: secondary exposure to testosterone. Reference ID 021015s044. 2019. accessdata.fda.gov